title: Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.
abstract: BACKGROUND
  The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).
  
  
  METHODS
  In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.
  
  
  RESULTS
  Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).
  
  
  CONCLUSIONS
  Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.
authors.affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Mizushige
authors.affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kobori
authors.affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nishijima
authors.affiliation: Jichi Medical University School of Medicine, Tochigi, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Yano
authors.affiliation: Miyazaki University School of Medicine, Miyazaki, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Sakata
authors.affiliation: Miyazaki University School of Medicine, Miyazaki, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Hayakawa
authors.affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Nishiyama
mesh_terms: D000368:Aged; D000418:Albumins / Q000737:chemistry; D000808:Angiotensinogen / Q000627:therapeutic use / Q000652:urine*; D015415:Biomarkers / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007564:Japan; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000150:complications / Q000652:urine*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage*; D011379:Prognosis; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000418:Albumins; D015415:Biomarkers; D007004:Hypoglycemic Agents; D010880:Piperidines; D000808:Angiotensinogen; D014498:Uracil; D003404:Creatinine; C520853:alogliptin